Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ANI Pharmaceuticals Stock Down 1.6%

ANI Pharmaceuticals stock traded down $1.23 during midday trading on Tuesday, hitting $74.53. 526,173 shares of the stock were exchanged, compared to its average volume of 341,915. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 16.06 and a beta of 0.44. The business’s 50-day moving average price is $81.00 and its 200-day moving average price is $79.18. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ANIP shares. Canaccord Genuity Group decreased their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.83.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth about $2,706,000. Finally, Norges Bank bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $625,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.